CN101304749A - 用于腺泡型横纹肌肉瘤的星孢菌素衍生物 - Google Patents

用于腺泡型横纹肌肉瘤的星孢菌素衍生物 Download PDF

Info

Publication number
CN101304749A
CN101304749A CNA2006800384359A CN200680038435A CN101304749A CN 101304749 A CN101304749 A CN 101304749A CN A2006800384359 A CNA2006800384359 A CN A2006800384359A CN 200680038435 A CN200680038435 A CN 200680038435A CN 101304749 A CN101304749 A CN 101304749A
Authority
CN
China
Prior art keywords
group
typically
phenyl
hydrogen
low alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800384359A
Other languages
English (en)
Chinese (zh)
Inventor
M·瓦赫特尔
B·W·沙费尔
R·阿姆斯特费茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of CN101304749A publication Critical patent/CN101304749A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800384359A 2005-11-14 2006-11-13 用于腺泡型横纹肌肉瘤的星孢菌素衍生物 Pending CN101304749A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73622205P 2005-11-14 2005-11-14
US60/736,222 2005-11-14

Publications (1)

Publication Number Publication Date
CN101304749A true CN101304749A (zh) 2008-11-12

Family

ID=37758863

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800384359A Pending CN101304749A (zh) 2005-11-14 2006-11-13 用于腺泡型横纹肌肉瘤的星孢菌素衍生物

Country Status (10)

Country Link
US (1) US7973032B2 (cg-RX-API-DMAC7.html)
EP (1) EP1951255A1 (cg-RX-API-DMAC7.html)
JP (1) JP5308820B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080067654A (cg-RX-API-DMAC7.html)
CN (1) CN101304749A (cg-RX-API-DMAC7.html)
AU (1) AU2006313724B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2629478C (cg-RX-API-DMAC7.html)
RU (1) RU2443421C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007054579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132479A1 (en) * 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
CA2253608A1 (en) * 1996-05-01 1997-11-06 Louis Vignati Therapeutic treatment for vegf related diseases
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
RU2269315C2 (ru) * 2004-05-24 2006-02-10 Рашид Кямиль Оглы Гусейнов Способ соединения сосудов и устройство для герметизации надреза сосуда и перерезания стенки сосуда

Also Published As

Publication number Publication date
JP2009515858A (ja) 2009-04-16
US7973032B2 (en) 2011-07-05
EP1951255A1 (en) 2008-08-06
CA2629478C (en) 2013-10-15
US20080280880A1 (en) 2008-11-13
RU2443421C2 (ru) 2012-02-27
KR20080067654A (ko) 2008-07-21
WO2007054579A1 (en) 2007-05-18
BRPI0618571A2 (pt) 2011-09-06
JP5308820B2 (ja) 2013-10-09
CA2629478A1 (en) 2007-05-18
AU2006313724A1 (en) 2007-05-18
AU2006313724B2 (en) 2010-12-23
RU2008123382A (ru) 2009-12-27

Similar Documents

Publication Publication Date Title
CN1582150B (zh) 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
AU2004244747B2 (en) Staurosporine derivatives for hypereosinophilic syndrome
AU2004262927B2 (en) Combinations comprising staurosporines
BRPI0411563B1 (pt) Uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida
CA2629478C (en) Staurosporine derivatives for use in alveolar rhabdomyosarcoma
AU2005313556B2 (en) Use of staurosporine derivatives for the treatment of multiple Myeloma
WO2006021456A1 (en) Combination comprising a staurosporine and a cyp3a4 inhibitor
WO2008043811A1 (en) Staurosporine derivatives and radiation
MX2008006287A (es) Derivados de estaurosporina para utilizarse en rabdomiosarcoma alveolar.
AU2008202050A1 (en) Combinations comprising staurosporines
AU2008201869A1 (en) Staurosporine derivatives for hypereosinophilic syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20081112